Advancing Bispecifics and Combination Therapy to the Clinic banner

Bi- and multi-specific antibodies and combination therapy are the way forward and five molecules have already been FDA approved and are on the market. Investigators working on novel approaches for activating the immune response and targeting otherwise intractable targets will share recent development and promising results. Learn strategies for ensuring the safety of new molecules while maximizing efficacy for a range of indications.